Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Mauser

Showing results (71-80 of 166) with videos related to

Pageof 17
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 25, 2010
Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia AP M W van Helden, P H P Kaijen, E P Mauser-Bunschoten, et al.
The New England Journal of Medicine|September 24, 1981
The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trialL J Sjamsoedin, L Heijnen, E P Mauser-Bunschoten, et al.
Thrombosis and Haemostasis|June 16, 1988
Bleeding symptoms in carriers of hemophilia A and BE P Mauser Bunschoten, J C van Houwelingen, E J Sjamsoedin Visser, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 10, 2001
Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia AE P Mauser-Bunschoten, J G van der Bom, M Bongers, et al.
Blood|January 5, 2002
Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia ATon Lisman, Laurent O Mosnier, Thierry Lambert, et al.
Scandinavian Journal of Gastroenterology|January 1, 1992
Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2B treatment in hemophilia patientsD Bresters, E P Mauser-Bunschoten, H T Cuypers, et al.
Thrombosis and Haemostasis|February 11, 2000
The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group AA J Vlot, E P Mauser-Bunschoten, A G Zarkova, et al.
Blood|January 11, 2007
Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort studyDirk Posthouwer, Michael Makris, Thynn T Yee, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 20, 2002
Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcomeK Fischer, J G Van Der Bom, R Prejs, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 14, 2001
Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathyK Fischer, J G van der Bom, E P Mauser-Bunschoten, et al.
Pageof 17

Showing results (71-80 of 166) with videos related to

Sort By:
Pageof 17
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 25, 2010
Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia AP M W van Helden, P H P Kaijen, E P Mauser-Bunschoten, et al.
The New England Journal of Medicine|September 24, 1981
The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trialL J Sjamsoedin, L Heijnen, E P Mauser-Bunschoten, et al.
Thrombosis and Haemostasis|June 16, 1988
Bleeding symptoms in carriers of hemophilia A and BE P Mauser Bunschoten, J C van Houwelingen, E J Sjamsoedin Visser, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 10, 2001
Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia AE P Mauser-Bunschoten, J G van der Bom, M Bongers, et al.
Blood|January 5, 2002
Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia ATon Lisman, Laurent O Mosnier, Thierry Lambert, et al.
Scandinavian Journal of Gastroenterology|January 1, 1992
Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2B treatment in hemophilia patientsD Bresters, E P Mauser-Bunschoten, H T Cuypers, et al.
Thrombosis and Haemostasis|February 11, 2000
The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group AA J Vlot, E P Mauser-Bunschoten, A G Zarkova, et al.
Blood|January 11, 2007
Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort studyDirk Posthouwer, Michael Makris, Thynn T Yee, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 20, 2002
Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcomeK Fischer, J G Van Der Bom, R Prejs, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 14, 2001
Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathyK Fischer, J G van der Bom, E P Mauser-Bunschoten, et al.
Pageof 17